Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024)
Guideline Development Group of Clinical Practice Guidelines for Meropenem Therapy in Neonatal Sepsis; PekingUniversity Third Hospital; Editorial Department of Chinese Journal of Contemporary Pediatrics
Abstract：Meropenem is one of the most widely used special-grade antimicrobial agents in the treatment of neonatal sepsis. However, its irrational use has led to an increasingly severe problem of bacterial multidrug resistance. The guideline was developed following standardized methods and procedures, and provides 12 recommendations specifically addressing 9 clinical issues. The recommendations cover various aspects of meropenem use in neonates, including timing of administration, recommended dosage, extended infusion, monitoring and assessment, antimicrobial adjustment strategies, treatment duration, and treatment strategies for carbapenem-resistant Enterobacteriaceae infections. The aim of the guideline is to provide evidence-based recommendations and guidance for the rational use of meropenem in neonates with sepsis.
Guideline Development Group of Clinical Practice Guidelines for Meropenem Therapy in Neonatal Sepsis,PekingUniversity Third Hospital,Editorial Department of Chinese Journal of Contemporary Pediatric. Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024)[J]. CJCP, 2024, 26(2): 107-117.
Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, et al. The global burden of paediatric and neonatal sepsis: a systematic review[J]. Lancet Respir Med, 2018, 6(3): 223-230. PMID: 29508706. DOI: 10.1016/S2213-2600(18)30063-8.
Prusakov P, Goff DA, Wozniak PS, et al. A global point prevalence survey of antimicrobial use in neonatal intensive care units: the no-more-antibiotics and resistance (NO-MAS-R) study[J]. EClinicalMedicine, 2021, 32: 100727. PMID: 33554094. PMCID: PMC7848759. DOI: 10.1016/j.eclinm.2021.100727.
Chen Y, Yang K, Maru?ic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166(2): 128-132. PMID: 27893062. DOI: 10.7326/M16-1565.
Zhou P, Cheng Y, Cao G, et al. The OBTAINS study: a nationwide cross-sectional survey on the implementation of extended or continuous infusion of β-lactams and vancomycin among neonatal sepsis patients in China[J]. Front Pharmacol, 2022, 13: 1001924. PMID: 36299905. PMCID: PMC9589050. DOI: 10.3389/fphar.2022.1001924.
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358: j4008. PMID: 28935701. PMCID: PMC5833365. DOI: 10.1136/bmj.j4008.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605. PMID: 20652370. DOI: 10.1007/s10654-010-9491-z.
Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations[J]. BMC Med, 2022, 20(1): 23. PMID: 35022047. PMCID: PMC8753858. DOI: 10.1186/s12916-021-02204-0.
Norris SL, Meerpohl JJ, Akl EA, et al. The skills and experience of GRADE methodologists can be assessed with a simple tool[J]. J Clin Epidemiol, 2016, 79: 150-158.e1. PMID: 27421684. DOI: 10.1016/j.jclinepi.2016.07.001.
Guyatt GH, Alonso-Coello P, Schünemann HJ, et al. Guideline panels should seldom make good practice statements: guidance from the GRADE working group[J]. J Clin Epidemiol, 2016, 80: 3-7. PMID: 27452192. DOI: 10.1016/j.jclinepi.2016.07.006.
Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive[J]. BMJ, 2008, 337: a744. PMID: 18669566. DOI: 10.1136/bmj.a744.
Polin RA, Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis[J]. Pediatrics, 2012, 129(5): 1006-1015. PMID: 22547779. DOI: 10.1542/peds.2012-0541.
31 National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management in people with cancer: clinical guideline [CG151][EB/OL]. (2012-09-19)[2024-01-10]. https://www.nice.org.uk/guidance/cg151.
Tsai MH, Chu SM, Hsu JF, et al. Risk factors and outcomes for multidrug-resistant gram-negative bacteremia in the NICU[J]. Pediatrics, 2014, 133(2): e322-e329. PMID: 24420803. DOI: 10.1542/peds.2013-1248.
Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children[J]. Intensive Care Med, 2020, 46(Suppl 1): 10-67. PMID: 32030529. PMCID: PMC7095013. DOI: 10.1007/s00134-019-05878-6.
Davis AL, Carcillo JA, Aneja RK, et al. The American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: executive summary[J]. Pediatr Crit Care Med, 2017, 18(9): 884-890. PMID: 28723883. PMCID: PMC8341147. DOI: 10.1097/PCC.0000000000001259.
Al-Matary A, Al Sulaiman M, Al-Otaiby S, et al. Association between the timing of antibiotics administration and outcome of neonatal sepsis[J]. J Infect Public Health, 2022, 15(6): 643-647. PMID: 35617827. DOI: 10.1016/j.jiph.2022.05.004.
Sankar J, Garg M, Ghimire JJ, et al. Delayed administration of antibiotics beyond the first hour of recognition is associated with increased mortality rates in children with sepsis/severe sepsis and septic shock[J]. J Pediatr, 2021, 233: 183-190.e3. PMID: 33359300. DOI: 10.1016/j.jpeds.2020.12.035.
Lima-Rogel V, Olguín-Mexquitic L, Kühn-Córdova I, et al. Optimizing meropenem therapy for severe nosocomial infections in neonates[J]. J Pharm Sci, 2021, 110(10): 3520-3526. PMID: 34089712. DOI: 10.1016/j.xphs.2021.05.019.
Smith PB, Cohen-Wolkowiez M, Castro LM, et al. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections[J]. Pediatr Infect Dis J, 2011, 30(10): 844-849. PMID: 21829139. PMCID: PMC3173561. DOI: 10.1097/INF.0b013e31822e8b0b.
Leegwater E, Wewerinke L, de Grauw AM, et al. Optimization of β-lactam dosing regimens in neonatal infections: continuous and extended administration versus intermittent administration[J]. Clin Pharmacokinet, 2023, 62(5): 715-724. PMID: 36972008. DOI: 10.1007/s40262-023-01230-w.
Shabaan AE, Nour I, Elsayed Eldegla H, et al. Conventional versus prolonged infusion of meropenem in neonates with gram-negative late-onset sepsis: a randomized controlled trial[J]. Pediatr Infect Dis J, 2017, 36(4): 358-363. PMID: 27918382. DOI: 10.1097/INF.0000000000001445.
Yu Z, Pang X, Wu X, et al. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis[J]. PLoS One, 2018, 13(7): e0201667. PMID: 30059536. PMCID: PMC6066326. DOI: 10.1371/journal.pone.0201667.
Taccone FS, Laterre PF, Dugernier T, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock[J]. Crit Care, 2010, 14(4): R126. PMID: 20594297. PMCID: PMC2945087. DOI: 10.1186/cc9091.
Taccone FS, Laupland KB, Montravers P. Continuous infusion of β-lactam antibiotics for all critically ill patients?[J]. Intensive Care Med, 2016, 42(10): 1604-1606. PMID: 26831672. DOI: 10.1007/s00134-016-4241-7.
Florea NR, Kotapati S, Kuti JL, et al. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study[J]. Am J Health Syst Pharm, 2003, 60(22): 2321-2327. PMID: 14652981. DOI: 10.1093/ajhp/60.22.2321.
Loeuille G, D'Huart E, Vigneron J, et al. Stability studies of 16 antibiotics for continuous infusion in intensive care units and for performing outpatient parenteral antimicrobial therapy[J]. Antibiotics (Basel), 2022, 11(4): 458. PMID: 35453211. PMCID: PMC9030478. DOI: 10.3390/antibiotics11040458.
De Waele JJ, Schouten J, Beovic B, et al. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions: a viewpoint of experts[J]. Intensive Care Med, 2020, 46(2): 236-244. PMID: 32025778. PMCID: PMC7224113. DOI: 10.1007/s00134-019-05871-z.
Puopolo KM, Benitz WE, Zaoutis TE, et al. Management of neonates born at ≥35 0/7 weeks' gestation with suspected or proven early-onset bacterial sepsis[J]. Pediatrics, 2018, 142(6): e20182894. PMID: 30455342. DOI: 10.1542/peds.2018-2894.
McMullan BJ, Andresen D, Blyth CC, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines[J]. Lancet Infect Dis, 2016, 16(8): e139-e152. PMID: 27321363. DOI: 10.1016/S1473-3099(16)30024-X.
Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis[J]. Clin Infect Dis, 2004, 39(9): 1267-1284. PMID: 15494903. DOI: 10.1086/425368.
Nabarro LEB, Shankar C, Pragasam AK, et al. Clinical and bacterial risk factors for mortality in children with carbapenem-resistant Enterobacteriaceae bloodstream infections in India[J]. Pediatr Infect Dis J, 2017, 36(6): e161-e166. PMID: 28005691. DOI: 10.1097/INF.0000000000001499.
Wang J, Lv Y, Yang W, et al. Epidemiology and clinical characteristics of infection/colonization due to carbapenemase-producing Enterobacterales in neonatal patients[J]. BMC Microbiol, 2022, 22(1): 177. PMID: 35820815. PMCID: PMC9277881. DOI: 10.1186/s12866-022-02585-z.
Weng B, Zhang X, Hong W, et al. A case of sepsis due to carbapenem-resistant Klebsiella pneumoniae in an extremely low-birth weight infant treated with trimethoprim-sulfamethoxazole[J]. Infect Drug Resist, 2021, 14: 2321-2325. PMID: 34188498. PMCID: PMC8235925. DOI: 10.2147/IDR.S312183.
Alanezi G, Almulhem A, Aldriwesh M, et al. A triple antimicrobial regimen for multidrug-resistant Klebsiella pneumonia in a neonatal intensive care unit outbreak: a case series[J]. J Infect Public Health, 2022, 15(1): 138-141. PMID: 34742638. DOI: 10.1016/j.jiph.2021.10.008.
